All systems operational
For Researchers
For Publishers
Login
Register
عربي
Submit Journal
عربي
Navigation
01
Discover
02
Rankings
03
For Publishers
04
About AMS
Back to Menu
Discover
By type
Journals
Research Papers
Authors
Institutions
Publishers
Affiliates
By Field
Medicine & Health Sciences
Engineering & Technology
Natural Sciences
Social Sciences
Computer Science & AI
All 98 fields →
By Country
🇸🇦 Saudi Arabia
🇪🇬 Egypt
🇯🇴 Jordan
🇦🇪 UAE
🇲🇦 Morocco
All 22 countries →
Tools
DOI Lookup
ISSN Search
Rankings
Journal rankings
AMS Score Ranking
Citation Impact (CIF)
Quartile Rankings Q1–Q4
Open Access Index
Rising Stars
People & places
Authors Ranking
Institutions Ranking
Country Ranking
By subject
Medicine & Health
Engineering
Computer Science
Natural Sciences
All rankings →
For Publishers
Get indexed
Journal Indexing
Indexing Criteria
Packages & Pricing
Review Timeline
Benefits
Global visibility — 22 countries
AMS Score badge
AMS Certification
Real-time analytics dashboard
REST API access
Resources
Publisher Sign In
Register
API Documentation
Publisher FAQ
About AMS
Platform
What is AMS?
Our Methodology
Quality Standards
News & Updates
Technical
API Documentation
Data Sources
System Status
Resources
Research Reports
Annual Statistics
Press Kit
FAQ
Contact Us
Login
Register
Affiliates
For Researchers
Submit Journal
Home
Authors
Mohamed A. Kharfan-Dabaja
MK
Mohamed A. Kharfan-Dabaja
h-7
H-Index
152
Citations
15
Papers
Published Papers
15 indexed
1
The Risk and Prognosis of COVID-19 Infection in Cancer Patients
Hematology/Oncology and Stem Cell Therapy
Q3
2022
10.1016/j.hemonc.2020.07.005
80
citations
398
2
Lisocabtagene Maraleucel in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Hematology/Oncology and Stem Cell Therapy
Q3
2022
10.1016/j.hemonc.2021.09.004
12
citations
394
3
CAR-T cell Therapies for B-cell Lymphoid Malignancies
Hematology/Oncology and Stem Cell Therapy
Q3
2022
10.56875/2589-0646.1026
9
citations
389
4
C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel ☆
Hematology/Oncology and Stem Cell Therapy
Q3
2021
10.1016/j.hemonc.2020.09.004
8
citations
390
5
Management of CAR T-cell Related Toxicities
Hematology/Oncology and Stem Cell Therapy
Q3
2022
10.56875/2589-0646.1029
8
citations
390
6
Intraocular involvement of Mantle cell lymphoma
Hematology/Oncology and Stem Cell Therapy
Q3
2021
10.1016/j.hemonc.2019.03.002
7
citations
387
7
Predictors and Management of Relapse to Axicabtagene Ciloleucel in Patients with Aggressive B-cell Lymphoma ☆
Hematology/Oncology and Stem Cell Therapy
Q3
2023
10.1016/j.hemonc.2021.09.001
7
citations
391
8
Efficacy of Allogeneic Hematopoietic Cell Transplantation in Patients With Chronic Phase CML Resistant or Intolerant to Tyrosine Kinase Inhibitors
Hematology/Oncology and Stem Cell Therapy
Q3
2022
10.1016/j.hemonc.2021.02.003
6
citations
393
9
Post-Autologous Hematopoietic Cell Transplant Care in the “Home Sweet Home” Setting: A Treatment Paradigm Shift
Hematology/Oncology and Stem Cell Therapy
Q3
2023
10.56875/2589-0646.1088
6
citations
392
10
Understanding the Etiology of Pancytopenias in the CAR T-Cell Therapy Setting
Hematology/Oncology and Stem Cell Therapy
Q3
2022
10.56875/2589-0646.1047
4
citations
390
11
Emerging Role of Autologous CD19 CAR T-Cell Therapies in the Second-Line Setting for Large B-cell Lymphoma
Hematology/Oncology and Stem Cell Therapy
Q3
2022
10.56875/2589-0646.1025
3
citations
391
12
Relapse of Hodgkin lymphoma after autologous hematopoietic cell transplantation
Hematology/Oncology and Stem Cell Therapy
Q3
2021
10.1016/j.hemonc.2020.05.011
1
citations
390
13
Allogeneic hematopoietic cell transplantation as the standard of care for blastic plasmacytoid dendritic cell neoplasm in first complete remission
Hematology/Oncology and Stem Cell Therapy
Q3
2025
10.4103/hemoncstem.hemoncstem-d-25-00023
1
citations
385
14
Effect of Somatic Variants Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Hematology/Oncology and Stem Cell Therapy
Q3
2025
10.4103/hemoncstem.hemoncstem-d-25-00029
0
citations
392
15
Impact of mental health on outcomes of patients with relapsed and/or refractory diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy
Hematology/Oncology and Stem Cell Therapy
Q3
2026
10.4103/hemoncstem.hemoncstem-d-26-00018
0
citations
389
Publication Activity
Journals Published In
HOST
Hematology/Oncology and Stem Cell Therapy
🇸🇦
Q3
AMS 72